Spectrum Management Group’s Pacira BioSciences PCRX Stock Holding History

Spectrum Management Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$32K	Hold	600	–	–	0.01%	159
2022 Q2	$35K	Hold	600	–	–	0.01%	152
2022 Q1	$46K	Hold	600	–	–	0.01%	163
2021 Q4	$36K	Hold	600	–	–	0.01%	166
2021 Q3	$34K	Hold	600	–	–	0.01%	208
2021 Q2	$36K	Hold	600	–	–	0.01%	167
2021 Q1	$42K	Hold	600	–	–	0.01%	155
2020 Q4	$36K	Hold	600	–	–	0.01%	151
2020 Q3	$36K	Hold	600	–	–	0.01%	157
2020 Q2	$31K	Hold	600	–	–	0.01%	161
2020 Q1	$20K	Hold	600	–	–	0.01%	160
2019 Q4	$27K	Hold	600	–	–	0.01%	173
2019 Q3	$23K	Hold	600	–	–	0.01%	168
2019 Q2	$26K	Hold	600	–	–	0.01%	178
2019 Q1	$23K	Hold	600	–	–	0.01%	170
2018 Q4	$26K	Hold	600	–	–	0.01%	146
2018 Q3	$29K	Hold	600	–	–	0.01%	150
2018 Q2	$19K	Sell	600 -4,018	-87%	-$139K	0.01%	171
2018 Q1	$144K	Hold	4,618	–	–	0.05%	88
2017 Q4	$211K	Buy	4,618 +200	+5%	+$7.93K	0.07%	81
2017 Q3	$166K	Buy	+4,418	New	+$178K	0.05%	124
2016 Q2	–	Sell	-4,018	Closed	-$213K	–	182
2016 Q1	$213K	Hold	4,018	–	–	0.08%	80
2015 Q4	$309K	Buy	4,018 +360	+10%	+$20.4K	0.12%	54
2015 Q3	$150K	Buy	3,658 +168	+5%	+$10.3K	0.08%	56
2015 Q2	$247K	Buy	+3,490	New	+$275K	0.09%	38
2015 Q1	–	Sell	-3,205	Closed	-$284K	–	134
2014 Q4	$284K	Sell	3,205 -90	-3%	-$8.51K	0.12%	34
2014 Q3	$319K	Sell	3,295 -1,295	-28%	-$126K	0.2%	33
2014 Q2	$422K	Hold	4,590	–	–	0.26%	30
2014 Q1	$321K	Buy	4,590 +295	+7%	+$20.1K	0.23%	30
2013 Q4	$247K	Buy	+4,295	New	+$226K	0.18%	33

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Spectrum Management Group's PCRX Position: Q3 2022 in Review

Spectrum Management Group held its Pacira BioSciences (PCRX) position steady in Q3 2022 at 600 shares worth $32K. The position accounts for 0.01% of the portfolio, ranked #159.

Spectrum Management Group first reported a position in PCRX in Q4 2013 and has held it in 30 quarters since. The position peaked at $422K in Q2 2014. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Spectrum Management Group held 600 shares of Pacira BioSciences worth $32K as of Q3 2022.
Spectrum Management Group left its Pacira BioSciences share count unchanged in Q3 2022.
Pacira BioSciences made up 0.01% of Spectrum Management Group's portfolio in Q3 2022, its #159 holding.
Spectrum Management Group first reported a position in Pacira BioSciences in Q4 2013 and has held it in 30 quarters since.
Spectrum Management Group's Pacira BioSciences position peaked at $422K in Q2 2014.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Spectrum Management Group's 13F filing for Q3 2022, filed 1 Nov 2022.